Does PPI therapy predispose to Clostridium difficile infection?

Chaitanya Pant(Overton Brooks VA Medical Center), Phillip Madonia(Louisiana State University), Anil Minocha(Overton Brooks VA Medical Center)
Nature Reviews Gastroenterology & Hepatology
August 28, 2009
10.1038/nrgastro.2009.128
Cited by 29

Abstract

Related Papers

Emergence of Fluoroquinolones as the Predominant Risk Factor for Clostridium difficile-Associated Diarrhea: A Cohort Study during an Epidemic in Quebec
Jean‐Louis Pépin, Nabil Saheb, Marie‐Andrée Coulombe et al.|Clinical Infectious Diseases|2005|996
Health Care Costs and Mortality Associated with Nosocomial Diarrhea Due to Clostridium difficile
Lorraine Kyne, M. B. Hamel, Raju Polavaram et al.|Clinical Infectious Diseases|2002|905
Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression
Jennifer Leonard, John K. Marshall, Paul Moayyedi|The American Journal of Gastroenterology|2007|640
A Large Outbreak of<i>Clostridium difficile</i>–Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone Use
Carlene A. Muto, Marian Pokrywka, Kathleen A. Shutt et al.|Infection Control and Hospital Epidemiology|2005|619
Clostridium difficile Infection Caused by the Epidemic BI/NAP1/027 Strain
Jennifer R. O’Connor, Stuart Johnson, Dale N. Gerding|Gastroenterology|2009|359